Peter F. Lebowitz
6Patents
3h-index
5Co-inventors
46Inventor score
Filing activity: Oct 8, 2010 → Oct 28, 2019
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8703781B2 | Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors | Human Necessities | 12 | Active |
| US8952018B2 | Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors | Human Necessities | 10 | Active |
| US10869869B2 | Method of adjuvant cancer treatment | Human Necessities | 8 | Active |
| US8796298B2 | Combination of a B-Raf inhibitor: N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1- dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide and the Akt inhibitor: N-{ (1S)-2-amino-1-[(3- fluorophenyl)methyl]ethyl}-5-chIoro-4-(4-chIoro- 1 -methyl- 1 H-pyrazol-5-yl)-2-10 thiophenecarboxamide useful in the treatment of cancer | Human Necessities | 0 | Active |
| US8835450B2 | Combination of inhibitor of B-Raf and an inhibitor of Akt in the treatment of cancer | Human Necessities | 0 | Active |
| US9402846B2 | Combination of inhibitor of B-Raf and inhibitor of AKT in the treatment of cancer | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.